Sleep

DSIP

Emideltide, delta sleep-inducing peptide

DSIP is a nine-amino-acid peptide first isolated in the 1970s from animals in deep sleep. It is not FDA-approved, and older human sleep studies produced weak or inconsistent results.

Key facts

  • Commonly discussed for: sleep quality and insomnia.
  • Evidence (C): Human evidence consists of small trials from the 1980s and early 1990s; a double-blind study of 16 chronic insomniacs found weak effects and concluded DSIP was unlikely to be of major therapeutic value.
  • FDA status: Not recommended. On July 24, 2026 the PCAC voted 6-7 (1 abstention) against adding emideltide (DSIP) to the 503A Bulks List for opioid withdrawal, insomnia and narcolepsy, the only peptide rejected at that meeting.
  • Legitimate access: No clear legal route yet.
  • Last reviewed: October 1, 2026.

Read the deep dives

Sources